Day 1 Morning: Peripheral Arterial & Acute Limb Ischaemia & Randomised Control Trial Update - Tuesday, 25th April
Venue: Kensington 1 / Livestream 1
Time: 08:00 - 13:00
Peripheral Arterial Consensus Update
Time: 08:00 - 09:40
| Anchor: | Roger Greenhalgh, London, United Kingdom |
| Moderators: | Andrew Holden, Auckland, New Zealand |
| Dittmar Boeckler, Heidelberg, Germany |
08:00 - 08:05
Edited Case: Is transradial the new approach for peripheral artery treatment
| Speaker: | Marianne Brodmann, Graz, Austria |
08:05 - 08:10
Audience Participation & Discussion
08:10 - 08:15
SFA Intervention - What DES data suggest are best
| Speaker: | Peter Schneider, San Francisco, United States |
08:15 - 08:20
Audience Participation & Discussion
08:20 - 08:25
Predictors of drug-coated balloon efficacy in femoropopliteal intervention: Insights from a patient-level pooled analysis
| Speaker: | Marianne Brodmann, Graz, Austria |
08:25 - 08:30
Audience Participation & Discussion
08:30 - 08:35
Edited Case: Optimising PTA following atherectomy in complex lower limb lesions: 12-month results of the DISSECT study
| Speaker: | Michael Lichtenberg, Arnsberg, Germany |
08:35 - 08:40
Audience Participation & Discussion
08:40 - 08:45
Directional atherectomy followed by drug-coated balloons to treat long, calcified femoropopliteal artery lesions: The REALITY study
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
08:45 - 08:50
Audience Participation & Discussion
08:50 - 08:55
Increasing supervised exercise therapy capacity for claudication without additional vascular resource: The advantage of integrating public health services into vascular clinical pathways
| Speaker: | Naseer Ahmad, Manchester, United Kingdom |
08:55 - 09:00
Audience Participation & Discussion
09:00 - 09:05
Edited Case: MIMICS-3D 3-year results: Compelling clinical outcomes in complex patients and lesions
| Speaker: | Michael Lichtenberg, Arnsberg, Germany |
09:05 - 09:10
Audience Participation & Discussion
09:10 - 09:15
Five-year outcomes of drug-coated balloon treatment for femoropopliteal artery disease: DCB safety and effectiveness across real-world subgroups / reintervention patterns among patients with in-stent restenosis, long lesions, and chronic total occlusions
| Speaker: | Gunnar Tepe, Rosenheim, Germany |
09:15 - 09:20
Audience Participation & Discussion
09:20 - 09:25
A patient-level pooled analysis of drug-coated balloons versus bare metal stents for the treatment of symptomatic femoropopliteal disease
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
09:25 - 09:30
Audience Participation & Discussion
09:30 - 09:35
Challenging the status quo of SFA treatment
| Speaker: | Maarit Venermo, Helsinki, Finland |
09:35 - 09:40
Audience Participation & Discussion
Sponsored Education
Time: 09:40 - 10:10
Coffee Break
Time: 10:10 - 10:30
Acute Limb Ischaemia Consensus Update
Time: 10:30 - 10:40
| Anchor: | Roger Greenhalgh, London, United Kingdom |
| Moderator: | Gunnar Tepe, Rosenheim, Germany |
10:30 - 10:35
Podium First: Primary endpoint results of the STRIDE trial on thrombectomy for acute limb ischemia
| Speaker: | Sean Lyden, Cleveland, United States |
10:35 - 10:40
Audience Participation & Discussion
Sponsored Education
Time: 10:40 - 11:10
Randomised Control Trial Consensus Update
Time: 11:10 - 13:00
BASIL-2 Podium First Presentation
Time: 11:10 - 13:00
| Anchor: | Roger Greenhalgh, London, United Kingdom |
| Moderators: | Andrew Holden, Auckland, New Zealand |
| Dittmar Boeckler, Heidelberg, Germany |
Opening remarks and introduction
| Speaker: | Andrew Bradbury, Birmingham, United Kingdom |
The journey from BASIL-1 to BASIL-2
| Speaker: | Lewis Meecham, Worcester, United Kingdom |
Methodology: Statistical considerations
| Speaker: | Catherine Moakes, Birmingham, United Kingdom |
Methodology: Clinical considerations
| Speaker: | Gareth Bate, Solihull, United Kingdom |
Prospective cohort study: Putting BASIL-2 in context
| Speaker: | Matthew Popplewell, Shrewsbury, United Kingdom |
Limitations: Statistical considerations
| Speaker: | Catherine Moakes, Birmingham, United Kingdom |
Limitations: Clinical considerations
| Speaker: | Andrew Bradbury, Birmingham, United Kingdom |
Interpretation and future work
| Speaker: | Andrew Bradbury, Birmingham, United Kingdom |
11:40 - 13:00
Audience Participation & Roundtable Discussion
| Anchor: | Roger Greenhalgh, London, United Kingdom |
| Moderators: | Andrew Holden, Auckland, New Zealand |
| Dittmar Boeckler, Heidelberg, Germany | |
| Discussant: | Jess Stonehouse, London, United Kingdom |
| Eleni Whatley, Silver Spring, United States |
Lunch Break
Time: 13:00 - 13:30